Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Patient Demographics and Clinical Diagnosis
2.2. EGFR Mutation
2.3. KRAS Mutation
2.4. ALK Rearrangement
2.5. MET Amplification and Mutation
2.6. Other Driver Gene Alterations
2.7. Overlaps of Driver Gene Alterations
2.8. Passenger Gene Alterations
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Next Generation Sequencing
4.3. Multiplex PCR
4.4. FISH
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Karachaliou, N.; Mayo, C.; Costa, C.; Magri, I.; Gimenez-Capitan, A.; Molina-Vila, M.A.; Rosell, R. KRAS mutations in lung cancer. Clin. Lung Cancer 2013, 14, 205–214. [Google Scholar] [CrossRef] [PubMed]
- Da Cunha Santos, G.; Shepherd, F.A.; Tsao, M.S. EGFR mutations and lung cancer. Annu. Rev. Pathol. 2011, 6, 49–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gahr, S.; Stoehr, R.; Geissinger, E.; Ficker, J.H.; Brueckl, W.M.; Gschwendtner, A.; Gattenloehner, S.; Fuchs, F.S.; Schulz, C.; Rieker, R.J.; et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: Data from daily practice. Br. J. Cancer 2013, 109, 1821–1828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, W.; McQuitty, E.B.; Olsen, R.; Fan, H.; Hendrickson, H.; Tio, F.O.; Newton, K.; Cagle, P.T.; Jagirdar, J. EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma. Arch. Pathol. Lab. Med. 2014, 138, 543–545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arrieta, O.; Cardona, A.F.; Martin, C.; Mas-Lopez, L.; Corrales-Rodriguez, L.; Bramuglia, G.; Castillo-Fernandez, O.; Meyerson, M.; Amieva-Rivera, E.; Campos-Parra, A.D.; et al. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J. Thorac. Oncol. 2015, 10, 838–843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gimbrone, N.T.; Sarcar, B.; Gordian, E.R.; Rivera, J.I.; Lopez, C.; Yoder, S.J.; Teer, J.K.; Welsh, E.A.; Chiappori, A.A.; Schabath, M.B.; et al. Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. J. Thorac. Oncol. 2017, 12, 1851–1856. [Google Scholar] [CrossRef]
- Arrieta, O.; Cardona, A.F.; Federico Bramuglia, G.; Gallo, A.; Campos-Parra, A.D.; Serrano, S.; Castro, M.; Aviles, A.; Amorin, E.; Kirchuk, R.; et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J. Thorac. Oncol. 2011, 6, 1955–1959. [Google Scholar] [CrossRef] [Green Version]
- Cress, W.D.; Chiappori, A.; Santiago, P.; Munoz-Antonia, T. Lung cancer mutations and use of targeted agents in Hispanics. Rev. Recent. Clin. Trials 2014, 9, 225–232. [Google Scholar] [CrossRef] [Green Version]
- Cortes-Funes, H.; Gomez, C.; Rosell, R.; Valero, P.; Garcia-Giron, C.; Velasco, A.; Izquierdo, A.; Diz, P.; Camps, C.; Castellanos, D.; et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 2005, 16, 1081–1086. [Google Scholar] [CrossRef]
- Lopez-Chavez, A.; Thomas, A.; Evbuomwan, M.O.; Xi, L.; Chun, G.; Vidaurre, T.; Arrieta, O.; Oblitas, G., 3rd; Oton, A.B.; Calvo, A.R.; et al. EGFR Mutations in Latinos from the United States and Latin America. J. Glob. Oncol. 2016, 2, 259–267. [Google Scholar] [CrossRef]
- Dong, Z.Y.; Zhong, W.Z.; Zhang, X.C.; Su, J.; Xie, Z.; Liu, S.Y.; Tu, H.Y.; Chen, H.J.; Sun, Y.L.; Zhou, Q.; et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin. Cancer Res. 2017, 23, 3012–3024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skoulidis, F.; Goldberg, M.E.; Greenawalt, D.M.; Hellmann, M.D.; Awad, M.M.; Gainor, J.F.; Schrock, A.B.; Hartmaier, R.J.; Trabucco, S.E.; Gay, L.; et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018, 8, 822–835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dogan, S.; Shen, R.; Ang, D.C.; Johnson, M.L.; D’Angelo, S.P.; Paik, P.K.; Brzostowski, E.B.; Riely, G.J.; Kris, M.G.; Zakowski, M.F.; et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin. Cancer Res. 2012, 18, 6169–6177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Osta, B.; Behera, M.; Kim, S.; Berry, L.D.; Sica, G.; Pillai, R.N.; Owonikoko, T.K.; Kris, M.G.; Johnson, B.E.; Kwiatkowski, D.J.; et al. Characteristics and Outcomes of Patients with Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J. Thorac. Oncol. 2019, 14, 876–889. [Google Scholar] [CrossRef] [PubMed]
- Bubendorf, L.; Buttner, R.; Al-Dayel, F.; Dietel, M.; Elmberger, G.; Kerr, K.; Lopez-Rios, F.; Marchetti, A.; Oz, B.; Pauwels, P.; et al. Testing for ROS1 in non-small cell lung cancer: A review with recommendations. Virchows Arch. 2016, 469, 489–503. [Google Scholar] [CrossRef] [PubMed]
- Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511, 543–550. [Google Scholar] [CrossRef]
- Sterlacci, W.; Fiegl, M.; Gugger, M.; Bubendorf, L.; Savic, S.; Tzankov, A. MET overexpression and gene amplification: Prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. Virchows Arch. 2017, 471, 49–55. [Google Scholar] [CrossRef]
- Yu, H.A.; Arcila, M.E.; Rekhtman, N.; Sima, C.S.; Zakowski, M.F.; Pao, W.; Kris, M.G.; Miller, V.A.; Ladanyi, M.; Riely, G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19, 2240–2247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Leary, C.G.; Andelkovic, V.; Ladwa, R.; Pavlakis, N.; Zhou, C.; Hirsch, F.; Richard, D.; O’Byrne, K. Targeting BRAF mutations in non-small cell lung cancer. Transl. Lung Cancer Res. 2019, 8, 1119–1124. [Google Scholar] [CrossRef] [PubMed]
- Garrido-Castro, A.C.; Felip, E. HER2 driven non-small cell lung cancer (NSCLC): Potential therapeutic approaches. Transl. Lung Cancer Res. 2013, 2, 122–127. [Google Scholar] [CrossRef]
- Gainor, J.F.; Varghese, A.M.; Ou, S.H.; Kabraji, S.; Awad, M.M.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M.; Yeap, B.Y.; Riely, G.J.; et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19, 4273–4281. [Google Scholar] [CrossRef] [Green Version]
- Chia, P.L.; Mitchell, P.; Dobrovic, A.; John, T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol. 2014, 6, 423–432. [Google Scholar] [CrossRef] [Green Version]
- Salgia, R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol. Cancer Ther. 2017, 16, 555–565. [Google Scholar] [CrossRef] [Green Version]
- Wang, Q.; Yang, S.; Wang, K.; Sun, S.Y. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J. Hematol. Oncol. 2019, 12, 63. [Google Scholar] [CrossRef]
- Cappuzzo, F.; Marchetti, A.; Skokan, M.; Rossi, E.; Gajapathy, S.; Felicioni, L.; Del Grammastro, M.; Sciarrotta, M.G.; Buttitta, F.; Incarbone, M.; et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 2009, 27, 1667–1674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sweis, R.F.; Thomas, S.; Bank, B.; Fishkin, P.; Mooney, C.; Salgia, R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus 2016, 8, e513. [Google Scholar] [CrossRef] [Green Version]
- Lee, T.; Lee, B.; Choi, Y.L.; Han, J.; Ahn, M.J.; Um, S.W. Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. J. Pathol. Transl. Med. 2016, 50, 197–203. [Google Scholar] [CrossRef] [Green Version]
- Li, W.; Qiu, T.; Guo, L.; Ling, Y.; Gao, Y.; Ying, J.; He, J. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Lett. 2018, 423, 9–15. [Google Scholar] [CrossRef]
- Assi, H.; Tfayli, A.; Assaf, N.; Daya, S.A.; Bidikian, A.H.; Kawsarani, D.; Fermanian, P.; Zaatari, G.; Mahfouz, R. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: A first report from a major tertiary care center. Mol. Biol. Rep. 2019, 46, 3671–3676. [Google Scholar] [CrossRef]
- Roman, M.; Baraibar, I.; Lopez, I.; Nadal, E.; Rolfo, C.; Vicent, S.; Gil-Bazo, I. KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Mol. Cancer 2018, 17, 33. [Google Scholar] [CrossRef] [Green Version]
- Cai, D.; Hu, C.; Li, L.; Deng, S.; Yang, J.; Han-Zhang, H.; Li, M. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. Cancer Med. 2020, 9, 84–93. [Google Scholar] [CrossRef] [PubMed]
- Soh, J.; Toyooka, S.; Matsuo, K.; Yamamoto, H.; Wistuba, I.I.; Lam, S.; Fong, K.M.; Gazdar, A.F.; Miyoshi, S. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncol. Lett. 2015, 10, 1775–1782. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reinersman, J.M.; Johnson, M.L.; Riely, G.J.; Chitale, D.A.; Nicastri, A.D.; Soff, G.A.; Schwartz, A.G.; Sima, C.S.; Ayalew, G.; Lau, C.; et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J. Thorac. Oncol. 2011, 6, 28–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferrer, I.; Zugazagoitia, J.; Herbertz, S.; John, W.; Paz-Ares, L.; Schmid-Bindert, G. KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer 2018, 124, 53–64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Facchinetti, F.; Bluthgen, M.V.; Tergemina-Clain, G.; Faivre, L.; Pignon, J.P.; Planchard, D.; Remon, J.; Soria, J.C.; Lacroix, L.; Besse, B. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer 2017, 112, 62–68. [Google Scholar] [CrossRef] [PubMed]
- Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069–1075. [Google Scholar] [CrossRef]
- Lasorella, A.; Sanson, M.; Iavarone, A. FGFR-TACC gene fusions in human glioma. Neuro Oncol. 2017, 19, 475–483. [Google Scholar] [CrossRef] [Green Version]
- Helsten, T.; Elkin, S.; Arthur, E.; Tomson, B.N.; Carter, J.; Kurzrock, R. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 2016, 22, 259–267. [Google Scholar] [CrossRef] [Green Version]
- Sun, X.; Zuo, K.; Yao, Q.; Zhou, S.; Shui, R.; Xu, X.; Bi, R.; Yu, B.; Cheng, Y.; Tu, X.; et al. Invasive apocrine carcinoma of the breast: Clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod. Pathol. 2020. [Google Scholar] [CrossRef]
Variables | Number (%) |
---|---|
Gender | |
Male | 501 (52.7%) |
Female | 450 (47.3%) |
Age (years) | |
Median (range) | 70 (35–95) |
Mean ± SD | 69 ± 10.43 |
<60 years | 187 (19.7%) |
≥60 years | 764 (80.3%) |
Diagnosis | |
Adenocarcinoma | 717 (75.4%) |
Squamous cell carcinoma | 144 (15.1%) |
Others | 90 (9.5%) |
Genes | Incidence | Reported Incidence | p-Value |
---|---|---|---|
EGFR | 24.0% (187/780) | 26.0% (1491/5738) [5] | p = 0.2282 |
Exon 19 deletion | 55.1% (103/187) | 47.1% (702/1491) [5] | p = 0.0391 † |
Exon 21 L858R | 31.0% (58/187) | 37.3% (556/1491) [5] | p = 0. 0931 |
Exon 20 S768I | 1.6% (3/187) | 3.1% (12/382) [7] | p = 0.2824 |
T790M | 0.5% (4/780) | 1.4% (85/5738) [5] | p = 0.0268 † |
Others | 10.2% (19/187) | N/A | N/A |
KRAS | 18.7% (77/411) | 14.0% (190/1355) [5] | p = 0.0195 † |
ALK | 3.9% (28/710) | 4.2–10.5% [8] | N/A |
ROS1 | 2.2% (7/322) | 0.7–3.4% [15] | N/A |
RET | 2.1% (4/190) | 1.0–3.0% [16] | N/A |
MET (Amplification) | 10.2% (18/172) | 2–20% [2,16,17,18] | N/A |
BRAF | 4.3% (4/94) | 1–5% [19] | N/A |
ERBB2 | 5.8% (4/69) | 2–5% [20] | N/A |
Genes | Gender | Age | |||||
---|---|---|---|---|---|---|---|
Male | Female | p-Value | Median (Years) | <60 Years | ≥60 Years | p-Value | |
EGFR | 15.5% | 33.2% | p < 0.00001 † | 68 | 30.1% | 19.5% | p = 0.0075 † |
(63/407) | (124/373) | (46/153) | (80/410) | ||||
KRAS | 21.0% | 16.1% | p = 0.1991 | 72 | 13.5% | 29.9% | p = 0.0052 † |
(46/219) | (31/193) | (10/74) | (67/224) | ||||
ALK | 3.4% | 4.6% | p = 0.4335 | 66.5 | 7.1% | 3.3% | p = 0.0446 † |
(13/381) | (15/329) | (9/127) | (19/583) | ||||
MET | 7.4% | 14.3% | p = 0.1406 | 66 | 20.0% | 8.8% | p = 0.0920 |
(7/95) | (11/77) | (5/25) | (13/147) |
Gene Mutations | Percentage |
---|---|
KRAS | |
Condon 12 | 97.4% (75/77) |
G12C | 40.3% (31/77) |
G12V | 18.2% (14/77) |
G12D | 23.4% (18/77) |
G12A | 6.5% (5/77) |
KRAS + TP53 | 3.6% (2/55) |
KRAS + STK11 | 3.6% (2/55) |
Genes | Positive (n) | Tested (n) | Percentage (%) |
---|---|---|---|
TP53 | 30 | 55 | 54.6 |
STK11 | 6 | 55 | 10.9 |
FGFR1 | 6 | 55 | 10.9 |
PIK3CA | 5 | 55 | 9.1 |
IGF1 | 5 | 55 | 9.1 |
DDR2 | 4 | 55 | 7.3 |
MDM2 | 3 | 55 | 5.5 |
PTEN | 2 | 55 | 3.6 |
FGFR2 | 2 # | 55 | 3.6 |
FGFR3 | 2 | 55 | 3.6 |
HRAS | 1 | 55 | 1.8 |
PDGFRA | 1 | 55 | 1.8 |
BCL2 | 1 | 55 | 1.8 |
AKT1 | 0 | 55 | 0 |
ARAF | 0 | 55 | 0 |
MAP2K1 | 0 | 55 | 0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zheng, R.; Yin, Z.; Alhatem, A.; Lyle, D.; You, B.; Jiang, A.S.; Liu, D.; Jobbagy, Z.; Wang, Q.; Aisner, S.; et al. Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico. Cancers 2020, 12, 3492. https://doi.org/10.3390/cancers12123492
Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang AS, Liu D, Jobbagy Z, Wang Q, Aisner S, et al. Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico. Cancers. 2020; 12(12):3492. https://doi.org/10.3390/cancers12123492
Chicago/Turabian StyleZheng, Ruifang, Zhiwei Yin, Albert Alhatem, Derek Lyle, Bei You, Andrew S. Jiang, Dongfang Liu, Zsolt Jobbagy, Qing Wang, Seena Aisner, and et al. 2020. "Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico" Cancers 12, no. 12: 3492. https://doi.org/10.3390/cancers12123492